arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

PROTHENA CORP PUBLIC LTD CO

PRTA
$8.74 ▲ +0.17 (+1.92%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
59 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
21
Health
Poor
Bearish
auto_awesome

Analytical Summary

PROTHENA CORP PUBLIC LTD CO faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $469.4M
Dividend Yield
Revenue Growth 1706.4%
Op. Margin 58.8%
ROIC 9.6%
FCF / Share $0.54
Trailing P/E 14.3x
Price / Book 1.5x
FCF Yield 6.2%
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

59-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$51.08M
↑ +1706.4%
Net Income Profit after all expenses
$32.72M
↑ +251.6%
Operating Margin Operating profit as % of sales
58.8%
↑ +33.0%
FCF / Share Free cash flow per share
$0.54
↑ +171.3%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
10
Cash Quality
47

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 16 years · 59 quarters